GB9210839D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB9210839D0
GB9210839D0 GB929210839A GB9210839A GB9210839D0 GB 9210839 D0 GB9210839 D0 GB 9210839D0 GB 929210839 A GB929210839 A GB 929210839A GB 9210839 A GB9210839 A GB 9210839A GB 9210839 D0 GB9210839 D0 GB 9210839D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929210839A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB929210839A priority Critical patent/GB9210839D0/en
Publication of GB9210839D0 publication Critical patent/GB9210839D0/en
Priority to JP5520016A priority patent/JPH07506591A/ja
Priority to CA002136196A priority patent/CA2136196A1/en
Priority to AU40814/93A priority patent/AU4081493A/en
Priority to PCT/GB1993/001014 priority patent/WO1993023401A1/en
Priority to EP93910221A priority patent/EP0641344A1/en
Priority to ZA933494A priority patent/ZA933494B/xx
Priority to CN93107586A priority patent/CN1094046A/zh
Priority to MX9302957A priority patent/MX9302957A/es
Priority to TW082104444A priority patent/TW277062B/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GB929210839A 1992-05-21 1992-05-21 Novel compounds Pending GB9210839D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds
EP93910221A EP0641344A1 (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors
PCT/GB1993/001014 WO1993023401A1 (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors
CA002136196A CA2136196A1 (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors
AU40814/93A AU4081493A (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors
JP5520016A JPH07506591A (ja) 1992-05-21 1993-05-18 ホスホジエステラーゼ阻害剤としての８−置換キサンチン
ZA933494A ZA933494B (en) 1992-05-21 1993-05-19 Xanthine phosphodiesterase inhibitors
CN93107586A CN1094046A (zh) 1992-05-21 1993-05-20 取代的黄嘌呤衍生物
MX9302957A MX9302957A (es) 1992-05-21 1993-05-20 Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
TW082104444A TW277062B (https=) 1992-05-21 1993-06-03

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds

Publications (1)

Publication Number Publication Date
GB9210839D0 true GB9210839D0 (en) 1992-07-08

Family

ID=10715834

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929210839A Pending GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds

Country Status (10)

Country Link
EP (1) EP0641344A1 (https=)
JP (1) JPH07506591A (https=)
CN (1) CN1094046A (https=)
AU (1) AU4081493A (https=)
CA (1) CA2136196A1 (https=)
GB (1) GB9210839D0 (https=)
MX (1) MX9302957A (https=)
TW (1) TW277062B (https=)
WO (1) WO1993023401A1 (https=)
ZA (1) ZA933494B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
WO1999024432A1 (fr) 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
ES2206227T3 (es) * 1999-05-11 2004-05-16 Mitsubishi Chemical Corporation Dihidrato de un derivado de purina, farmacos que lo contienen como ingrediente activo, e intermedio en su preparacion.
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
EP1208100B1 (en) * 1999-08-31 2003-04-02 Vanderbilt University Selective antagonists of a2b adenosine receptors
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
WO2003020724A1 (en) 2001-08-28 2003-03-13 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
CA2533715A1 (en) 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
CN101076343A (zh) 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779374D1 (en) * 1986-08-28 1992-07-02 Sandoz Ag Xanthinderivate.
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
ATE194345T1 (de) * 1990-12-21 2000-07-15 Beecham Group Plc Xanthinderivate

Also Published As

Publication number Publication date
CN1094046A (zh) 1994-10-26
CA2136196A1 (en) 1993-11-25
WO1993023401A1 (en) 1993-11-25
TW277062B (https=) 1996-06-01
AU4081493A (en) 1993-12-13
ZA933494B (en) 1994-03-01
EP0641344A1 (en) 1995-03-08
MX9302957A (es) 1994-05-31
JPH07506591A (ja) 1995-07-20

Similar Documents

Publication Publication Date Title
AP9300562A0 (en) Novel compounds
GB9210839D0 (en) Novel compounds
GB9202779D0 (en) Novel compounds
GB9203476D0 (en) Novel compounds
GB9204953D0 (en) Novel compounds
GB9203355D0 (en) Novel compounds
GB9200571D0 (en) Novel compounds
GB9211694D0 (en) Novel compounds
GB9205434D0 (en) Novel compounds
GB9205433D0 (en) Novel compounds
GB9205432D0 (en) Novel compounds
GB9205429D0 (en) Novel compounds
GB9205426D0 (en) Novel compounds
GB9205425D0 (en) Novel compounds
GB9205423D0 (en) Novel compounds
GB9205422D0 (en) Novel compounds
GB9205421D0 (en) Novel compounds
GB9205420D0 (en) Novel compounds
GB9205419D0 (en) Novel compounds
GB9205418D0 (en) Novel compounds
GB9205417D0 (en) Novel compounds
GB9205416D0 (en) Novel compounds
GB9203556D0 (en) Novel compounds
GB9205414D0 (en) Novel compounds
GB9205413D0 (en) Novel compounds